Observational studyJournal of neuro-oncology2021
Cyproterone acetate and meningioma: a nationwide-wide population based study.
Observational study in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- The Association Between Meningioma and Breast Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.Scientific reports · 2022Pooled it
- Exogenous Hormones and Their Clinical Implications for the Development and Growth of Meningioma Tumours.Journal of clinical medicine · 2026Review
- Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study.Neuro-oncology · 2026Article
- Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- The evolution of pediatric transgender healthcare in Flanders: Trends in referrals, intakes and gender-affirming interventions over the last 15 years.International journal of transgender health · 2026Article
- The Case for Neurosurgical Intervention in Cancer Neuroscience.Neurosurgery · 2025Review
- Paradoxical evolution of spheno-orbital meningioma after cessation of progestin treatment.Surgical neurology international · 2025Article
- Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015.Acta neurochirurgica · 2024Article
- Descriptive epidemiology of 30,223 histopathologically confirmed meningiomas in France: 2006-2015.Acta neurochirurgica · 2024Article
- The impact of testosterone-lowering medication on recidivism in individuals convicted of sexual offenses.Dialogues in clinical neuroscience · 2024Article
- Regression of Multiple Intracranial Meningiomas With Cessation of Progesterone Agonist Therapy: A Case Report.Cureus · 2024Article
- Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series.Therapeutic advances in endocrinology and metabolism · 2024Article
- Development and Growth of Intracranial Meningiomas in Transgender Women Taking Cyproterone Acetate as Gender-Affirming Progestogen Therapy: A Systematic Review.Transgender health · 2022Review
- Meningioma in patients exposed to progestin drugs: results from a real-life screening program.Journal of neuro-oncology · 2022Article
- Functional Outcome after Spinal Meningioma Surgery.Asian spine journal · 2022Article
- Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.Neurosurgical review · 2022Article
- Association of Hormonal Contraception with Meningioma Location in Indonesian Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Prediction of meningioma shrinkage after cyproterone acetate cessation.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study the characteristics of surgical meningiomas in female patients who took CPA and to compare this population to a non-CPA control group. MATERIALS AND
methodsWe processed the French Système National des Données de Santé (SNDS) database to retrieve appropriate cases operated between 2007 and 2017.
results1 101 female patients (3.8%) who used to take CPA and underwent a meningioma surgery were extracted from a nationwide population based cohort of 28 924 patients. Median age at CPA prescription was 42 years IQR[36.7-48.9]. The median time between CPA start and surgery was 5.5 years IQR[3.1-7.9]. The median age at surgery was significantly lower in patients who were treated by CPA (47 years, IQR[42-54) compared to the non-CPA population (61 years, IQR[51-70], p < 0.001). Median CPA dose was 40 g, IQR[19-72]. There was a strong correlation between CPA dose and duration (r = 0.58,
conclusionIn the past 10 years, a significant number of CPA-induced meningiomas have been removed, modifying the global pyramid of age at surgery for female patients. These tumours occur well before the usual age and are preferentially located on the anterior and middle skull base.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.